Status:
COMPLETED
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
Lead Sponsor:
Novartis
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart f...
Eligibility Criteria
Inclusion
- History of diagnosis or currently have high blood pressure
- Stable heart failure (NYHA Class 2-4) for at least 1 month before study entry. Subject should be on a stable dose regimen of heart failure medication.
- Brain natriuretic peptide (BNP) \> 150 pg/ml at baseline (to be evaluated by physician at first visit)
Exclusion
- Previous treatment with aliskiren
- High blood pressure due to secondary reasons or constant low blood pressure (systolic \< 90 mmHg)
- History of heart attack or coronary bypass surgery in the past 6 months
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00219011
Start Date
May 1 2005
End Date
February 1 2007
Last Update
May 17 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
2
Investigative Centers, Germany